Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831441 · ClinicalTrials.gov registry record · Phase 3
Phase III Acute Coronary Syndrome
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7,484
- Enrollment target
NCT00831441: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00831441 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7,484 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (869% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831441, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7,484 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
Primary Outcome
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemi
Interventions
- DRUG Placebo
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,484 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Why NCT00831441 stopped before completion
NCT00831441 is an interventional study that assigns participants to a tested intervention. Its 7,484 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (869% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00831441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00831441 about?
NCT00831441 is a clinical study titled "Phase III Acute Coronary Syndrome". The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
What is the current status of trial NCT00831441?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7,484 participants. The study started on 2009-03. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00831441?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00831441?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00831441's enrollment target sits among peer trials
7,484 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT06112418 · 7,500 participants · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia